RTTNews | Oct 7, 2021 08:27AM EDT

08:27 Thursday, October 7, 2021 (RTTNews.com) - Providing an update regarding the FDA hold on its Investigational New Drug Application (IND) for SkinTE on Thursday, biotechnology company PolarityTE, Inc. (PTE) said it has developed a strong a plan to address the issues FDA identified and is currently working diligently to prepare a complete response.

PolarityTE has also informally engaged with the FDA on certain points raised by the agency regarding the proposed potency assays that the Company plans to implement.

PolarityTE believes the opportunity to receive additional guidance from FDA prior to submitting a complete response could help the Company comprehensively address the hold issues identified by FDA to ultimately support an IND acceptance.

The FDA had placed a clinical hold on August 24 on the study proposed in its IND for SkinTE with a proposed indication for chronic cutaneous ulcers. The IND application was filed on July 23, 2021.

Read the original article on RTTNews ( https://www.rttnews.com/3231174/polarityte-says-it-developed-strong-plan-to-address-clinical-hold-on-ind-for-skinte-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved